These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 21412723)

  • 1. Future therapeutical strategies dictated by pre-clinical evidence in ALS.
    Fornai F; Meininger V; Silani V
    Arch Ital Biol; 2011 Mar; 149(1):169-74. PubMed ID: 21412723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introducing Amyotrophic lateral sclerosis.
    Silani V; Meininger V; Fornai F
    Arch Ital Biol; 2011 Mar; 149(1):1-4. PubMed ID: 21412712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Update on fundamental and clinical research in amyotrophic lateral sclerosis].
    Pradat PF; Camdessanché JP; Carluer L; Cintas P; Corcia P; Danel-Brunaud V; Echaniz-Laguna A; Gonzalez J; Nicolas G; Vandenberghe N; Verschueren A;
    Rev Neurol (Paris); 2009; 165(6-7):532-41. PubMed ID: 19419744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed cell death in amyotrophic lateral sclerosis: a mechanism of pathogenic and therapeutic importance.
    Przedborski S
    Neurologist; 2004 Jan; 10(1):1-7. PubMed ID: 14720310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyotrophic lateral sclerosis--the tools of the trait.
    Lederer CW; Santama N
    Biotechnol J; 2007 May; 2(5):608-21. PubMed ID: 17345579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translating biological findings into new treatment strategies for amyotrophic lateral sclerosis (ALS).
    Poppe L; Rué L; Robberecht W; Van Den Bosch L
    Exp Neurol; 2014 Dec; 262 Pt B():138-51. PubMed ID: 25017368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for clinical approach to neurodegeneration in Amyotrophic lateral sclerosis.
    Carlesi C; Pasquali L; Piazza S; Lo Gerfo A; Caldarazzo Ienco E; Alessi R; Fornai F; Siciliano G
    Arch Ital Biol; 2011 Mar; 149(1):151-67. PubMed ID: 21412722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution, differentiation, and survival of intravenously administered neural stem cells in a rat model of amyotrophic lateral sclerosis.
    Mitrecić D; Nicaise C; Gajović S; Pochet R
    Cell Transplant; 2010; 19(5):537-48. PubMed ID: 20350352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New therapy options for amyotrophic lateral sclerosis.
    Gordon P; Corcia P; Meininger V
    Expert Opin Pharmacother; 2013 Oct; 14(14):1907-17. PubMed ID: 23855817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined immunosuppressive agents or CD4 antibodies prolong survival of human neural stem cell grafts and improve disease outcomes in amyotrophic lateral sclerosis transgenic mice.
    Yan J; Xu L; Welsh AM; Chen D; Hazel T; Johe K; Koliatsos VE
    Stem Cells; 2006 Aug; 24(8):1976-85. PubMed ID: 16644922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyotrophic lateral sclerosis and frontotemporal dementia (ALS-FTD).
    Zago S; Poletti B; Morelli C; Doretti A; Silani V
    Arch Ital Biol; 2011 Mar; 149(1):39-56. PubMed ID: 21412715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop.
    Ludolph AC; Bendotti C; Blaugrund E; Hengerer B; Löffler JP; Martin J; Meininger V; Meyer T; Moussaoui S; Robberecht W; Scott S; Silani V; Van Den Berg LH;
    Amyotroph Lateral Scler; 2007 Aug; 8(4):217-23. PubMed ID: 17653919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental models of amyotrophic lateral sclerosis.
    Elliott JL
    Neurobiol Dis; 1999 Oct; 6(5):310-20. PubMed ID: 10527800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atypical motor neuron disease and related motor syndromes.
    Verma A; Bradley WG
    Semin Neurol; 2001 Jun; 21(2):177-87. PubMed ID: 11442326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot study of granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood stem cells in amyotrophic lateral sclerosis (ALS).
    Cashman N; Tan LY; Krieger C; Mädler B; Mackay A; Mackenzie I; Benny B; Nantel S; Fabros M; Shinobu L; Yousefi M; Eisen A
    Muscle Nerve; 2008 May; 37(5):620-5. PubMed ID: 18335482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffusion tensor MRI of early upper motor neuron involvement in amyotrophic lateral sclerosis.
    Sach M; Winkler G; Glauche V; Liepert J; Heimbach B; Koch MA; Büchel C; Weiller C
    Brain; 2004 Feb; 127(Pt 2):340-50. PubMed ID: 14607785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of stem cell therapies in amyotrophic lateral sclerosis.
    Srivastava AK
    Neurol India; 2014; 62(3):239-48. PubMed ID: 25033844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translating preclinical insights into effective human trials in ALS.
    DiBernardo AB; Cudkowicz ME
    Biochim Biophys Acta; 2006; 1762(11-12):1139-49. PubMed ID: 16713196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical trials--an update on translational research in ALS.
    Ludolph AC; Sperfeld AD
    Neurodegener Dis; 2005; 2(3-4):215-9. PubMed ID: 16909028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mini-Review: Induced pluripotent stem cells and the search for new cell-specific ALS therapeutic targets.
    Ferraiuolo L; Maragakis NJ
    Neurosci Lett; 2021 Jun; 755():135911. PubMed ID: 33892003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.